Pharmaceuticals: Novo in line, Sanofi not bad in underlying and AstraZeneca with further focus in oncology
Today reported Q1 numbers for Novo-Nordisk, Sanofi and AstraZeneca should not result in major share price reactions overall. Novo was very much in line. Sanofi, once restated from reclassification and Venezuela was not bad at all and AstraZeneca had soft quarter as expected and is announcing new restructuring to further focus on oncology and de-prioritize inflammation beyond respiratory.
For more information, please contact email@example.com